y Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/ Refractory Diffuse Large B-Cell Lymphoma

被引：16

作者：

Jaeger, Ulrich ^{[1
]}

Worel, Nina ^{[2
]}

McGuirk, Joseph P. ^{[3
]}

Riedell, Peter A. ^{[4
]}

Fleury, Isabelle ^{[5
,6
]}

Borchmann, Peter ^{[7
]}

Chu, Jufen ^{[8
]}

Abdelhady, Ahmed M. ^{[8
]}

Forcina, Alessandra ^{[9
]}

Pacaud, Lida Bubuteishvili ^{[8
]}

Waller, Edmund K. ^{[10
]}

机构：

[1] Med Univ Vienna, Dept Med 1, Clin Div Hematol & Hemostaseol, Vienna Gen Hosp, Vienna, Austria

[2] Med Univ Vienna, Transfus Med, Vienna, Austria

[3] Univ Kansas, Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Kansas City, KS 66103 USA

[4] Univ Chicago, Dept Med, Sect Hematol Oncol, 5841 S Maryland Ave, Chicago, IL 60637 USA

[5] Maisonneuve Rosemont Hosp, Montreal, PQ, Canada

[6] Univ Montreal, Montreal, PQ, Canada

[7] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany

[8] Novartis Pharmaceut, E Hanover, NJ USA

[9] Novartis Pharma AG, Basel, Switzerland

[10] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

来源：

关键词：

D O I：

10.1182/blood-2019-129120

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

5325

引用

页数：4